Circio Holding ASA (OSE: CRNA), a biotechnology firm focused on circular RNA and immunotherapy medicines, has dosed the first patient in the phase 2 trial sponsored by Georgetown University.
The study evaluates the mutant RAS cancer vaccine TG01 in combination with daratumumab (Janssen) and nivolumab (BMS) for patients with RAS-mutated pancreatic cancer (PDAC) and anti-PD1 resistant non-small cell lung cancer (NSCLC). RAS mutations, prevalent in over 90% of PDAC and 30% of NSCLC patients, pose a significant challenge with limited targeted treatment options.
The phase 2 trial, enrolling 54 KRAS-mutated patients, aims to address this unmet medical need in advanced PDAC and anti-PD1 resistant NSCLC.
TiumBio doses first patient in phase two TU2218 clinical trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Exact Sciences gains FDA approval for Cologuard Plus Test
Ferring expands gene therapy manufacturing capabilities
ImmunoPrecise subsidiary signs agreement with Biotheus for Antibody Evaluation in cancer therapy
UroGen Pharma doses first patient in Phase 3 trial of UGN-103 for bladder cancer
Immunovia announces completion of analytical validation of next-generation pancreatic cancer test
Owkin partners with AstraZeneca to Ddevelop AI Tool for gBRCA pre-screening in breast cancer
Leap Therapeutics completes enrollment for DeFianCe study evaluating DKN-01 in colorectal cancer